MAGNUS IHEMEDU: Open Payments
NPI 1649628322 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,633 in 321 payments from 16 companies in 2025. Trend: 2023 $3,469 · 2024 $4,686 · 2025 $6,633
Food & beverage: $6,420Education: $213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 83 | $1,712 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,060 |
| Janssen Pharmaceuticals, Inc | 35 | $771 |
| Otsuka America Pharmaceutical, Inc. | 37 | $680 |
| Neurocrine BioSciences, Inc. | 31 | $590 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $487 |
| Vanda Pharmaceuticals Inc. | 21 | $404 |
| E.R. Squibb & Sons, L.L.C. | 14 | $352 |
| Lundbeck LLC | 13 | $204 |
| Alkermes, Inc. | 11 | $171 |
Products named: VRAYLAR, REXULTI, AUSTEDO XR, INVEGA SUSTENNA, INGREZZA, CAPLYTA, COBENFY, FANAPT.
Industry payments across CA — which companies pay providers there.
